Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

Brian Mckeon Biography and Net Worth

CFO of IDEXX Laboratories

Mr. McKeon has been Executive Vice President, Chief Financial Officer, and Treasurer since January 2014. He leads our finance, corporate development and strategy and investor relations functions, and since June 2019, he has had oversight responsibility for our Water and Livestock, Poultry and Dairy business segments and the business of OPTI Medical Systems, Inc. In addition, from June 2019 to January 2020, Mr. McKeon had oversight responsibility over the Companion Animal Group business in Latin America. Mr. McKeon has served as a member of the board of directors of Alkermes plc since December 2020. Mr. McKeon served as a Director of IDEXX from July 2003 through December 2013, including serving as Chair of the Audit Committee and as a member of the Compensation Committee. He also served as a Director of athenahealth, Inc. from September 2017 to February 2019. Mr. McKeon was Executive Vice President of Iron Mountain Incorporated from April 2007 to December 2013 and Chief Financial Officer of Iron Mountain from April 2007 to October 2013. Mr. McKeon was also Executive Vice President and Chief Financial Officer of The Timberland Company from March 2000 to April 2007. From 1991 to 2000, Mr. McKeon held several finance and strategic planning positions with PepsiCo Inc., serving most recently as Vice President, Finance, at Pepsi-Cola, North America. Mr. McKeon holds a bachelor’s degree in accounting from the University of Connecticut and an M.B.A. with high distinction from Harvard University.

What is Brian P. Mckeon's net worth?: The estimated net worth of Brian P. Mckeon is at least $14.16 million as of February 7th, 2024. Mr. Mckeon owns 29,718 shares of IDEXX Laboratories stock worth more than $14,156,169 as of April 20th. This net worth evaluation does not reflect any other investments that Mr. Mckeon may own. Learn More about Brian P. Mckeon's net worth.
How do I contact Brian P. Mckeon?: The corporate mailing address for Mr. Mckeon and other IDEXX Laboratories executives is ONE IDEXX DRIVE, WESTBROOK ME, 04092. IDEXX Laboratories can also be reached via phone at (207) 556-0300 and via email at [email protected]. Learn More on Brian P. Mckeon's contact information.
Has Brian P. Mckeon been buying or selling shares of IDEXX Laboratories?: Brian P. Mckeon has not been actively trading shares of IDEXX Laboratories during the last ninety days. Most recently, Brian P. Mckeon sold 23,326 shares of the business's stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $570.01, for a transaction totalling $13,296,053.26. Following the completion of the sale, the chief financial officer now directly owns 29,718 shares of the company's stock, valued at $16,939,557.18. Learn More on Brian P. Mckeon's trading history.
Who are IDEXX Laboratories' active insiders?: IDEXX Laboratories' insider roster includes Jonathan Ayers (Director), Bruce Claflin (Director), George Fennell (SVP), Rebecca Henderson (Director), Nimrata Hunt (EVP), Daniel Junius (Director), Michael Lane (EVP), Jonathan Mazelsky (CEO), Brian Mckeon (CFO), James Polewaczyk (EVP), M. Szostak (Director), Kathy Turner (SVP), Kathy Turner (SVP), Giovani Twigge (SVP), and Sophie Vandebroek (Director). Learn More on IDEXX Laboratories' active insiders.
Are insiders buying or selling shares of IDEXX Laboratories?: During the last year, insiders at the sold shares 11 times. They sold a total of 127,835 shares worth more than $67,745,986.38. The most recent insider tranaction occured on February, 8th when SVP George Fennell sold 8,198 shares worth more than $4,704,586.26. Insiders at IDEXX Laboratories own 2.1% of the company. Learn More about insider trades at IDEXX Laboratories.
Information on this page was last updated on 2/8/2024.

Brian P. Mckeon Insider Trading History at IDEXX Laboratories

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/7/2024	Sell	23,326	$570.01	$13,296,053.26	29,718
11/9/2021	Sell	6,310	$630.22	$3,976,688.20
2/16/2021	Sell	1,307	$539.58	$705,231.06
11/6/2020	Sell	10,000	$476.25	$4,762,500.00	24,700
11/4/2020	Sell	36,216	$471.44	$17,073,671.04
8/14/2020	Sell	83,724	$378.97	$31,728,884.28	58,386
5/3/2019	Sell	7,504	$247.87	$1,860,016.48
2/5/2018	Sell	6,602	$181.36	$1,197,338.72	47,040
2/8/2017	Sell	9,924	$141.64	$1,405,635.36	45,235
2/8/2016	Sell	9,054	$69.65	$630,611.10	32,461
2/17/2015	Sell	5,000	$156.99	$784,950.00

Brian P. Mckeon Buying and Selling Activity at IDEXX Laboratories

IDEXX Laboratories Company Overview

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Today's Range

Now: $476.35

$471.42

$482.21

50 Day Range

MA: $538.02

$476.35

$576.87

2 Week Range

Now: $476.35

$372.50

$583.39

Volume

568,637 shs

Average Volume

429,223 shs

Market Capitalization

$39.56 billion

P/E Ratio

47.30

Dividend Yield

N/A

Beta

1.26